[{"NetIncomeLoss_1_Q2_USD":897300000.0,"OtherAssetsNoncurrent_0_Q2_USD":175500000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":1992200000.0,"Liabilities_0_Q2_USD":5371300000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":15800000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":44600000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"MarketableSecuritiesCurrent_0_Q2_USD":1152000000.0,"EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_0_Q2_USD":70600000.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":132000000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":35500000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":1010200000.0,"AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2_Q2_USD":119500000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q2_USD":416500000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":700000.0,"AssetsCurrent_0_Q2_USD":7860200000.0,"MarketableSecuritiesRealizedGainLoss_2_Q2_USD":28300000.0,"MarketableSecuritiesRealizedGainLoss_1_Q2_USD":28000000.0,"OtherNoncashIncomeExpense_2_Q2_USD":175800000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":715600000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":348300000.0,"FinanceLeaseLiabilityNoncurrent_0_Q2_USD":715900000.0,"TreasuryStockShares_0_Q2_shares":15578240.0,"LossContingencyAccrualAtCarryingValue_0_Q2_USD":132200000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":1355500000.0,"TreasuryStockValue_0_Q2_USD":6142900000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":941900000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":1536300000.0,"AccruedLiabilitiesAndOtherLiabilities_0_Q2_USD":1257000000.0,"IncreaseDecreaseInInventories_2_Q2_USD":233400000.0,"OtherOperatingIncomeExpenseNet_1_Q2_USD":50200000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":1305900000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":722000000.0,"EarningsPerShareBasic_2_Q2_USD":13.87,"EarningsPerShareBasic_1_Q2_USD":8.19,"EquitySecuritiesFvNiUnrealizedGainLoss_2_Q2_USD":171300000.0,"EquitySecuritiesFvNiUnrealizedGainLoss_1_Q2_USD":228100000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":116800000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":117900000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":246800000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":272200000.0,"AccountsReceivableNetCurrent_0_Q2_USD":1991000000.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":696900000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":65600000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":20900000.0,"TreasuryStockValueAcquiredCostMethod_1_Q2_USD":5071800000.0,"AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0_Q2_USD":1779600000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":114900000.0,"EffectiveIncomeTaxRateContinuingOperations_2_Q2_pure":0.041,"EffectiveIncomeTaxRateContinuingOperations_1_Q2_pure":0.024,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":-2277200000.0,"CostsAndExpenses_2_Q2_USD":2423700000.0,"CostsAndExpenses_1_Q2_USD":1295600000.0,"RestrictedCash_0_Q2_USD":12500000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":2843700000.0,"AccountsAndNotesReceivableNet_0_Q2_USD":431100000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":21600000.0,"OtherOperatingIncomeExpenseNet_2_Q2_USD":90600000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":2934500000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":44600000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":571600000.0,"ProceedsFromShortTermDebt_2_Q2_USD":1500000000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":105200000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":1641400000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":306300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":109700000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":109600000.0,"PaymentsToAcquireProductiveAssets_2_Q2_USD":300000000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0_Q2_USD":1152000000.0,"MarketableSecuritiesNoncurrent_0_Q2_USD":2587600000.0,"LiabilitiesCurrent_0_Q2_USD":3702400000.0,"NonoperatingIncomeExpense_2_Q2_USD":231000000.0,"NonoperatingIncomeExpense_1_Q2_USD":262500000.0,"InterestExpense_2_Q2_USD":15800000.0,"InterestExpense_1_Q2_USD":9700000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":2004700000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":263800000.0,"IncreaseDecreaseInDeferredIncomeTaxes_2_Q2_USD":-118000000.0,"AccountsPayableCurrentAndNoncurrent_0_Q2_USD":380100000.0,"AdditionalPaidInCapital_0_Q2_USD":6263000000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"OtherInventoryNetOfReserves_0_Q2_USD":505700000.0,"ShortTermBorrowings_0_Q2_USD":1500000000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":3031400000.0,"NetIncomeLoss_2_Q2_USD":1521900000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":44900000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":1533500000.0,"EarningsPerShareDiluted_1_Q2_USD":7.61,"EarningsPerShareDiluted_2_Q2_USD":13.03,"ShareBasedCompensation_2_Q2_USD":209300000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.01,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":2168000000.0,"DeferredIncomeTaxAssetsNet_0_Q2_USD":774000000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-33800000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":3780200000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":1952000000.0,"OperatingIncomeLoss_2_Q2_USD":1356500000.0,"OperatingIncomeLoss_1_Q2_USD":656400000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_Q2_USD":1587500000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q2_USD":918900000.0,"PaymentsForRepurchaseOfCommonStock_2_Q2_USD":5373600000.0,"Assets_0_Q2_USD":14428700000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_2_Q2_USD":-1400000.0,"InventoryNet_0_Q2_USD":1640900000.0,"PreferredStockValue_0_Q2_USD":0.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":14428700000.0,"PreferredStockSharesAuthorized_0_Q2_shares":30000000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":457900000.0,"OtherLiabilitiesCurrent_0_Q2_USD":103800000.0,"StockholdersEquity_0_Q2_USD":9057400000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":2890300000.0,"AccountsReceivableRelatedPartiesCurrent_0_Q2_USD":389200000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":8901700000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":374400000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":47100000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1_Q2_USD":0.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":78900000.0,"Ticker":"REGN","CIK":"872589","name":"REGENERON PHARMACEUTICALS, INC.","OfficialName":"Regeneron Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"77738004554.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"SP500","filed":"20200805"}]